Truveta delivers the most complete, timely, and clean electronic health record (EHR) data, including images, clinician notes, and labs from more than 30 health systems, empowering researchers with scientifically rigorous, fast, and compliant analytics. Truveta Data provides daily updated data from nearly 100 million de-identified patients in all 50 states from more than 800 hospitals and 20,000 clinics to provide a timely and representative view of patient care in the US.
It is an honor to partner with these innovative leaders across government, life sciences, academia, research, and healthcare to harness the power of timely, representative, complete, and clean EHR data to accelerate research across all diseases, drugs, and devices.
Using Truveta Data, these organizations will be able to pioneer groundbreaking clinical research, discover innovative new therapeutics, and advance patient care.”
Moderna to advance the clinical study of various rare diseases
Much of the data on rare diseases – such as disease stages, adverse events, medication change rationales, and disease symptoms – about rare disease patients are locked away in the clinical notes, making these data and clinical concepts challenging to access for medical research. Truveta uses advanced AI to extract and structure critical clinical concepts from notes so they can be analyzed alongside other critical, complete structured data from the EHR, like diagnoses and lab results, at the patient-level. Moderna will use these data to better understand patient journeys and identify potential new treatment pathways.
Being able to use Truveta Data to identify complete patient journeys – including from clinician notes – for those suffering from a rare disease means we can better understand the diseases to better inform our research and development decisions.
Our goal is to improve the care and outcomes for all patients, even those with the rarest of conditions.”
UCB to improve care for patients with rare inflammatory disease
Using Truveta Data to understand the HS patient journey—including sites of care and providers accessed across multiple specialties, intervention history, time to diagnosis, and more—is enabling UCB to better understand opportunities to improve provider education and facilitate earlier diagnosis and appropriate intervention. This, in turn, has the potential to limit disease progression, reduce unnecessary healthcare utilization, and improve HS patient quality of life.”
Boehringer Ingelheim to advance medical research for NASH
Through the power of AI, we can unlock critical patient insights at scale to help Boehringer Ingelheim advance the study of NASH and identify new potential treatment pathways.”
